2024-05-16 16:41:26 ET
Summary
- We recap Q1 developments from Pulse Biosciences, Inc.
- The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase.
- Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure.
Pulse Biosciences, Inc. ( PLSE ) continues to move forward with its pipeline of nanosecond pulsed field ablation (nsPFA) devices....
Read the full article on Seeking Alpha
For further details see:
Pulse Biosciences Stock: Signs Of Life Following Q1 Update